Correlation Between the Gut Microbiome and Response to Immunotherapy in Cancer Patients

Gordan Srkalovic, MD, PhDVenu Gangur, PhDPrincipal Investigators:
Gordan Srkalovic, MD, PhD, Director, Clinical Trials, Sparrow Cancer Center
Venu Gangur, PhD, Associate Professor; Director of Immunology Laboratory, Dept. Food Science and Human Nutrition, Michigan State University

The Long-term goal of this project is to elucidate the relationship between the gut microbial population diversity and the outcome of cancer immunotherapy in patients treated at the Sparrow Cancer Center. The Specific Aim of this proposal to establish an interdisciplinary project by conducting a feasibility pilot study.

DESCRIPTION OF STUDY: A prospective study will be conduced recruiting recruit 40 adult cancer patients with solid tumors (both gender) and 10 healthy adult control subjects. Patients with malignancies in which check point inhibitors are FDA approved treatments will be enrolled. Patient will be treated as per FDA approved regimens. Fecal and blood samples at multiple points will be collected during the treatment and analyzed for gut microbiome and immune markers at the Michigan State University. Correlation between response to immunotherapy and gut microbe diversity will be determined. Immune marker analysis will provide clues to mechanisms underlying any observed effects.

SIGNIFICANCE OF STUDY:
There is growing scientific evidence supporting the hypothesis that commensal microbial populations present in humans (commonly known as microbiome) have a significant impact on human health. More recent studies, surprisingly demonstrated the potential benefit of selected non-pathogenic gut bacteria on cancer immunotherapy using animal models of cancers